Class / Patent application number | Description | Number of patent applications / Date published |
514120700 | Relaxin or derivative | 27 |
20100286046 | MODIFIED H2 RELAXIN FOR TUMOR SUPPRESSION - Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor, but do not substantially activate the receptor once bound thereto The H2 relaxm antagonists are used in compositions and methods for the treatment of cancers wherein a relaxm receptor is expressed | 11-11-2010 |
20110003750 | HUMAN 3 RELAXIN - Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof. | 01-06-2011 |
20110039778 | Peptide Synthesis - A process for producing an insulin type peptide, for example a relaxin, involving oxidizing a methionine residue on a B-chain having cysteine residues and combining the B chain with an A chain having cysteine residues to form a peptide having intermolecular disulphide links and biological activity. Novel synthetic relaxin 1 and methionine oxidized relaxins and Met(O) B-chains having enhanced solubility are disclosed. | 02-17-2011 |
20110130332 | Relaxin Analogs - Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. | 06-02-2011 |
20110144019 | METHOD OF TREATING CHRONIC HEART FAILURE - The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin. | 06-16-2011 |
20110166070 | METHOD OF PREVENTING PREMATURE DELIVERY - The disclosure pertains to methods of decreasing the risk of premature birth and miscarriage in human females. Particularly, the disclosure provides methods of reducing cervical dialation and preterm delivery by administration of relaxin. | 07-07-2011 |
20110281801 | PREDICTION AND PREVENTION OF PREECLAMPSIA - The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman. | 11-17-2011 |
20120040903 | METHOD FOR TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE - The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin. | 02-16-2012 |
20120046229 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES - Modified relaxin polypeptides and their uses thereof are provided | 02-23-2012 |
20120238499 | METHODS OF MODULATING APOPTOSIS BY ADMINISTRATION OF RELAXIN AGONISTS OR ANTAGONISTS - The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject. | 09-20-2012 |
20130012441 | PREDICTION AND PREVENTION OF PREECLAMPSIA - The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing the risk of preeclampsia and treating it, once it has occurred by administering a pharmaceutical formulation of relaxin to a pregnant woman. | 01-10-2013 |
20130053318 | MODULATING AQUAPORINS WITH RELAXIN - The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin. | 02-28-2013 |
20130210730 | METHOD OF TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE - The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin. | 08-15-2013 |
20130237481 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES - Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided. | 09-12-2013 |
20130244938 | Relaxin Analogs - Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. | 09-19-2013 |
20130303455 | PREDICTION AND PREVENTION OF PREECLAMPSIA - The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing risk of preeclampsia through administration of a pharmaceutical formulation of relaxin to a pregnant woman. | 11-14-2013 |
20130324468 | METHODS OF TREATING DISEASES ASSOCIATED WITH PPARy - The invention relates to methods for modulating PPAR-γ activity using relaxin or agonists thereof. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including small vessel disorders of the brain and those associated with increased blood-brain barrier permeability, cognitive disorders such as Alzheimer's disease, vascular dementia, epilepsy, stroke, CADASIL and migraine. | 12-05-2013 |
20140005112 | METHOD OF TREATING CHRONIC HEART FAILURE BY ADMINISTERING RELAXIN | 01-02-2014 |
20140024592 | Modified Relaxin Polypeptides - The present invention relates to biologically active relaxin polypeptides comprising a relaxin A chain and a B chain derived from a relaxin superfamily member, wherein the A chain comprises no intra-chain disulphide bonds. In particular embodiments the modified polypeptides comprise relaxin-3 derived A and B chains, and truncations of the A and/or B chains from the N-termini and/or C-termini. In particular embodiments the polypeptides of the invention are selective agonists or antagonists of the RXFP3 receptor. | 01-23-2014 |
20140038895 | Single Chain Relaxin Polypeptides - The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor. | 02-06-2014 |
20140066377 | Modulating Aquaporins with Relaxin - The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin. | 03-06-2014 |
20140148390 | FUSION PROTEINS RELEASING RELAXIN AND USES THEREOF - The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending moiety and the linker comprises a protease cleavage site. Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, cells expressing the Relaxin fusion polypeptides, pharmaceutical compositions and medical use of such fusion polypeptides. | 05-29-2014 |
20140187491 | RELAXIN FUSION POLYPEPTIDES AND USES THEREOF - The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides. | 07-03-2014 |
20140194357 | Modified Relaxin Polypeptides and Their Uses - Modified relaxin polypeptides and their uses thereof are provided | 07-10-2014 |
20140256633 | Relaxin Proteins For Use In The Diagnosis, Prevention or Treatment of Multiple Sclerosis - The present invention relates to the use of one or more Relaxin proteins in methods for diagnoses and treatment of multiple sclerosis. The invention also provides compositions for use in diagnosing or treating multiple sclerosis as well as the methods themselves. Kits for carrying out the methods are also described. | 09-11-2014 |
20150031616 | USE OF RELAXIN TO TREAT PLACENTAL SYNDROMES - The subject application relates to methods for treating a placental syndrome, wherein relaxin is administered during the late secretory/luteal (LS) phase of the menstrual cycle in women who have a propensity for developing the placental syndrome. In certain embodiments, administration of relaxin continues beyond the LS phase and into pregnancy. | 01-29-2015 |
20150320834 | Method of treating dyspnea associated with acute heart failure - The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin. | 11-12-2015 |